AstraZeneca Withdraws Application for Lung Cancer Drug in the EU

AstraZeneca announced that it has voluntarily withdrawn its marketing authorization application to the EU drug regulator for an experimental precision medicine aimed at treating a type of lung cancer. The drug, called datopotamab deruxtecan, developed in collaboration with Japan's Daiichi Sankyo, was described earlier this month by the U.S. Food and Drug Administration as a breakthrough therapy for treating the same type of lung cancer after other treatments have failed.